公开(公告)号：EP1561759A4

公开(公告)日：2006-05-31

申请号：EP03751456

申请日：2003-10-10

申请人： CHUGAI PHARMACEUTICAL CO LTD ,  OZAKI SHUJI ,  ABE MASAHIRO

发明人： OZAKI SHUJI ,  ABE MASAHIRO ,  TSUCHIYA MASAYUKI ,  KIMURA NAOKI ,  KAWAI SHIGETO

IPC分类号： A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07K14/74 ,  C07K16/28 ,  C12P21/08 ,  C07K16/18 ,  A61K39/395

CPC分类号： C07K16/2833 ,  A61K2039/505 ,  C07K14/70539 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/73

摘要： In order to identify an antigen to 2D7 antibody, a 2D7 antigen is cloned. As a result, it is indicated that the 2D7 antigen is an HLA class I molecule. Based on this finding, it is discussed whether the 2D7 antibody has an activity of inducing cell death or not. As a result, nuclear fragmentation is observed by further crosslinking the 2D7 antibody with another antibody, thereby indicating that cell death is induced. It is also clarified that a diabody of the 2D7 antibody has an extremely strong cell death-inducing activity even though no other antibody is added. These results point out that a degradation product of an antibody recognizing HLA is usable as a cell death-inducing agent.

公开(公告)号：EP1757686A4

公开(公告)日：2008-03-12

申请号：EP04726750

申请日：2004-04-09

申请人： CHUGAI PHARMACEUTICAL CO LTD ,  OZAKI SHUJI ,  ABE MASAHIRO

发明人： OZAKI SHUJI ,  ABE MASAHIRO ,  TSUCHIYA MASAYUKI ,  KIMURA NAOKI ,  KAWAI SHIGETO

IPC分类号： C12N15/09 ,  A61K39/395 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2833 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73

摘要： Cloning of antigen 2D7 has been carried out to identify an antigen relevant to antibody 2D7. As a result, it has been found that the antibody 2D7 recognizes HLA class IA. Further, whether or not the antibody 2D7 has cell death inducing activity has been studied. As a result, it has been found that nuclear fragmentation is observed by crosslinking of the antibody 2D7 with another antibody to thereby bring about induction of cell death. Still further, it has been found that a diabody of antibody 2D7 exhibits very strong cell death inducing activity even when any other antibody is not added. These results suggest that an antibody with lowered molecular weight among antibodies capable of recognizing HLA can be utilized as a cell death inducer.

摘要翻译： 已经进行抗原2D7的克隆以鉴定与抗体2D7相关的抗原。 结果发现抗体2D7识别HLA类别IA。 此外，研究了抗体2D7是否具有细胞死亡诱导活性。 结果发现，通过抗体2D7与另一种抗体的交联观察到核碎裂，从而诱导细胞死亡。 还发现，即使没有加入任何其它抗体，抗体2D7的双抗体也显示非常强的细胞死亡诱导活性。 这些结果表明，能够识别HLA的抗体中具有降低的分子量的抗体可以用作细胞死亡诱导剂。

公开(公告)号：EP1927367A4

公开(公告)日：2009-08-12

申请号：EP06746578

申请日：2006-05-18

申请人： UNIV TOKUSHIMA ,  CHUGAI PHARMACEUTICAL CO LTD

发明人： MATSUMOTO TOSHIO ,  OZAKI SHUJI ,  ABE MASAHIRO

IPC分类号： A61K39/395 ,  A61K38/21 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/06 ,  A61P17/06 ,  A61P21/04 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P43/00

CPC分类号： C07K16/2833 ,  A61K38/212 ,  A61K38/217 ,  A61K39/3955 ,  C07K2317/73 ,  A61K2300/00

摘要： A test is performed on the effects of an interferon on the expression of HLA-A and the cytotoxicity caused by an anti-HLA class I antibody in a cell, using a 2D7-DB antibody as the anti-HLA class I antibody and an IM-9 cell strain as the cell to be tested. As a result, it is demonstrated that the expression of HLA-A can be up-regulated by IFNα and IFNϜ. Further, a WST-8 assay performed using an interferon and an anti-HLA class I antibody in combination to examine the cell viability demonstrates that cell death activity can be increased by the combination of 2D7-DB and IFNα or IFNϜ.

公开(公告)号：EP1364657A4

公开(公告)日：2006-03-29

申请号：EP02711350

申请日：2002-02-06

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： KOSAKA MASAAKI ,  OZAKI SHUJI ,  WAKAHARA YUJI

IPC分类号： A61K38/17 ,  A61K38/21 ,  A61K39/395 ,  A61P19/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/555 ,  C07K16/30 ,  C12N15/12 ,  G01N33/574 ,  A61K45/00 ,  C07K14/705 ,  C07K16/28 ,  C12Q1/02 ,  C12Q1/66 ,  C12Q1/68

CPC分类号： A61K39/3955 ,  A61K38/1709 ,  A61K38/21 ,  A61K38/212 ,  A61K38/217 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/555 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/732 ,  G01N33/57484 ,  A61K2300/00

摘要： HM1.24 antigen expression inducers or potentiators in tumor cells in hematopoietic organs which contain as the active ingredient interferon α, interferon β or IRF-2 protein; and antitumor agents for tumor in hematopoietic organs comprising these inducing agents or potentiators combined with an antibody against HM1.24.

摘要翻译： 用于在造血肿瘤细胞中表达HM1.24抗原的诱导剂或增强剂，其包含干扰素α，干扰素γ或IRF-2蛋白作为活性成分，以及用于造血肿瘤的抗肿瘤剂 包括所述诱导剂或增强剂与针对HM1.24的抗体的组合。

公开(公告)号：EP1213028A4

公开(公告)日：2003-01-02

申请号：EP00953561

申请日：2000-08-22

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： KOSAKA MASAAKI ,  OZAKI SHUJI ,  WAKAHARA YUJI

IPC分类号： A61K38/17 ,  A61K38/21 ,  A61K39/395 ,  A61P19/00 ,  A61P35/00 ,  C07K16/30 ,  A61K45/00 ,  G01N33/15 ,  G01N33/50

CPC分类号： C07K16/3061 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/217 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2300/00

摘要： Potentiators for the expression of HM1.24 antigen in myeloma cells which contain as the active ingredient interferon α, interferon η or IRF-2 protein. It is estimated that interferons α and η potentiate the expression of HM1.24 antigen through the activation of the promoter of a gene encoding HM1.24 antigen.